HP802-247

Phase 2Biologic

HHealthpoint

HP802-247 is one of 6 biologic programs targeting Dystrophic epidermolysis bullosa. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dystrophic Epidermolysis BullosaActive, not recruiting

Dystrophic Epidermolysis BullosaPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Dystrophic Epidermolysis Bullosa

#DrugCompanyPhaseTrials

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 2

1 2

Neupogen

EEastern Cooperative Oncology Group

Immunoglobulin G

1 4

HP802-247

HHealthpoint

Phase 2

1 5

ALLO-ASC-SHEET

AAnterogen Co., Ltd.

Phase 2

1 6

AGLE-102

AAegle Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Venous Leg Ulcers2 trials

Dose Finding Study of HP802-247 in Venous Leg Ulcers

Completed·HHealthpoint·Phase 2·NCT00852995·228 enrolled

A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

Terminated·HHealthpoint·Phase 2·NCT02154087·1 enrolled

Safety and Efficacy2 trials

Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

Terminated·HHealthpoint·Phase 3·NCT01853384·252 enrolled

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Completed·HHealthpoint·Phase 3·NCT01737762·155 enrolled

Venous Leg Ulcer1 trial

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

Unknown status·HHealthpoint··NCT01658618·440 enrolled

Survival1 trial

Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds

Completed·HHealthpoint·Phase 1·NCT01190865·28 enrolled

Dystrophic epidermolysis bullosa1 trial

A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa

Withdrawn·HHealthpoint·Phase 2·NCT01528306

1 more indication

Mohs Micrographic Surgery1 trial

Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients

Completed·HHealthpoint·Phase 2·NCT01359735·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for HP802-247. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HP802-247 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HP802-247. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healthpoint company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: HHealthpoint

HP802-247

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Venous Leg Ulcers2 trials

Safety and Efficacy2 trials

Venous Leg Ulcer1 trial

Survival1 trial

Dystrophic epidermolysis bullosa1 trial

Mohs Micrographic Surgery1 trial

References

Drug Info

Quick Facts

Related News